美国食品和药物管理局批准伊利利利的湿疹治疗,Ebglyss,用于12岁以上的成年人/儿童中度至重度的亚托皮炎. FDA approves Eli Lilly's eczema treatment, Ebglyss, for moderate-to-severe atopic dermatitis in adults/children 12+.

美国食品和药物管理局批准了Eli Lilly公司的湿疹治疗药物Ebglyss (lebrikizumab-lbkz),用于中度至重度的亚托皮炎的12岁及以上的成人和儿童. The FDA has approved Eli Lilly's eczema treatment, Ebglyss (lebrikizumab-lbkz), for adults and children aged 12 and older with moderate-to-severe atopic dermatitis. 批准之前,对1 000多名患者进行了三项研究,这些患者努力用现有治疗方法治疗其症状。 The approval follows three studies with over 1,000 patients who struggled to manage their symptoms with existing treatments. 这标志着与去年由于制造业方面的顾虑而遭拒绝的情况相比,出现了逆转。 This marks a reversal from last year's rejection due to manufacturing concerns. Ebglyss 将在未来几周内推出。 Ebglyss will be available in the coming weeks.